Dharti Proteins Limited (formerly Devika Proteins Limited) has submitted its quarterly compliance certificate under SEBI regulations to BSE Limited, confirming adherence to depository and participant regulations for the quarter ended 31st December, 2025.

Regulatory Compliance Filing

The company filed the mandatory certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 on 13th March, 2026. Managing Director Jatinbhai Ramanbhai Patel signed the submission letter to BSE Limited's Listing Department, ensuring the exchange maintains updated records of the company's regulatory compliance status.

Registrar Confirmation

System Support Services, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate from their Mumbai office. The registrar confirmed that all securities received from depository participants for dematerialization during Q3 FY26 were properly processed and either accepted or rejected to the depositories as required.

The certificate validates that securities comprised in the dematerialization certificates have been listed on stock exchanges where the company's previously issued securities are already listed. Additionally, the registrar confirmed compliance with procedural requirements for certificate handling and member register updates.

Dematerialization Process Compliance

The regulatory filing confirms adherence to key dematerialization protocols during the quarter. Security certificates received for dematerialization were mutilated and cancelled after due verification by depository participants, ensuring proper document handling as per SEBI guidelines.

Key compliance confirmations include:

• Proper acceptance or rejection of securities to depositories
• Listing of securities on appropriate stock exchanges
• Timely mutilation and cancellation of physical certificates
• Substitution of depository names in the register of members within 30 days

Company Information

Dharti Proteins Limited operates from its registered office in Ahmedabad, Gujarat, with CIN L67120GJ1994PLC022199. The company maintains its compliance communications through designated email channels and contact numbers as specified in the regulatory filing. The submission represents part of the company's ongoing quarterly regulatory obligations to maintain its listing status and ensure transparency in depository operations.

Dharti Proteins Limited (formerly Devika Proteins Limited) has scheduled a board meeting for March 18, 2026, to review and approve its third quarter financial performance for FY 2025-2026. The announcement was made through a formal communication to BSE Limited on March 13, 2026, in compliance with regulatory requirements.

Board Meeting Details

The upcoming board meeting represents the fourth board meeting of FY 2025-2026 for the Ahmedabad-based company. The meeting has been scheduled to address key financial matters and ensure timely disclosure of quarterly performance.

Key Agenda Items

The board meeting will focus on two primary matters. The directors will consider, discuss and approve the unaudited standalone financial results of the company for the third quarter and nine-months ended December 31, 2025. Additionally, the board will take on record the Limited Review Report accompanying these financial results.

The meeting agenda also includes provisions for considering any other matter with the permission of the chair, allowing flexibility for additional business items that may require board attention.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, demonstrating the company's commitment to maintaining transparency with stakeholders and adhering to prescribed disclosure timelines.

The communication was signed by Twinkle Bipinchandra Gajjar, Company Secretary and Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements.